Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer’s disease Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4. In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and address an unmet medical need. Key data being presented: MK-2214, an investigational novel antibody targeting phosphorylated serine 413 (pS413) tau: First presentation of data from three Phase 1 studies evaluating MK-2214. Two studies assessed the